Pemphigus in Cats: Welfare and Immunosuppressive Management

Pemphigus foliaceus is the most common autoimmune skin disease in cats, causing chronic welfare impacts from painful skin lesions and long-term immunosuppressive therapy.

Key Facts

Pemphigus foliaceus in cats causes pustule formation, crusting and erosions typically affecting the head, ears, face and nail beds
It is an autoimmune disease driven by autoantibodies against desmogleins in keratinocyte desmosomes
Long-term immunosuppressive therapy with corticosteroids, often in combination with chlorambucil or ciclosporin, is required for control
Complete remission occurs in some cases; many cats require ongoing management to prevent relapse

Welfare Considerations

Pemphigus foliaceus welfare involves a complex balance between disease control and immunosuppression side effects. Uncontrolled disease causes painful skin lesions, secondary bacterial infection and significant discomfort during manipulation. Aggressive immunosuppression achieves lesion control but creates susceptibility to opportunistic infections, gastrointestinal side effects and, in the long term, diabetes mellitus risk. Careful titration to the minimum effective dose of immunosuppressive therapy is the welfare-optimising approach, balancing disease control against treatment burden.

What You Can Do

Seek dermatology referral for diagnosis confirmation — pemphigus requires histopathology and immunohistochemistry
Implement combination immunosuppressive protocols to allow lower doses of individual drugs and reduce side effects
Monitor for opportunistic infections with regular clinical assessment and culture of new skin lesions
Taper immunosuppressive doses to the minimum effective maintenance level once remission is achieved